Results 11 to 20 of about 43,444 (242)

Imaging of Proteinopathies in the Brains of Parkinsonian Disorders. [PDF]

Cells
Neurodegenerative diseases such as Alzheimer’s disease (AD), frontotemporal lobar degeneration (FTLD), and α-synucleinopathies—including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)—are characterized by the accumulation of misfolded protein aggregates.
Higuchi M.
europepmc   +3 more sources

Co-occurrence of Convergence Insufficiency and Cognitive Impairment in Parkinsonian Disorders: A Pilot Study [PDF]

Frontiers in Neurology, 2019
Background: Convergence insufficiency (CI) in parkinsonian conditions causes disabling visual symptoms during near tasks and usually manifests as double vision.
Samantha K. Holden, Erin Van Dok, Victoria S. Pelak, Victoria S. Pelak   +3 more
doaj   +2 more sources

TSPO imaging in parkinsonian disorders. [PDF]

Clin Transl Imaging, 2016
Microglial activation is a key aspect of the neuroinflammatory process in neurodegenerative disorders including idiopathic and atypical parkinsonian disorders. With positron emission tomography (PET) it has become possible to image this phenomenon in vivo and over the last years patterns of microglia activation corresponding with the known distribution
Gerhard A.
europepmc   +6 more sources

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2019
Introduction Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative ...
Thilo vanEimeren, Angelo Antonini, Daniela Berg, Nico Bohnen, Roberto Ceravolo, Alexander Drzezga, Günter U. Höglinger, Makoto Higuchi, Stephane Lehericy, Simon Lewis, Oury Monchi, Peter Nestor, Matej Ondrus, Nicola Pavese, María Cecilia Peralta, Paola Piccini, José Ángel Pineda‐Pardo, Irena Rektorová, María Rodríguez‐Oroz, Axel Rominger, Klaus Seppi, A. Jon Stoessl, Alessandro Tessitore, Stephane Thobois, Valtteri Kaasinen, Gregor Wenning, Hartwig R. Siebner, Antonio P. Strafella, James B. Rowe, MDS Neuroimaging Study Group and the JPND Working Group ASAP‐SynTau   +29 more
doaj   +2 more sources

Nocturnal Manifestations of Atypical Parkinsonian Disorders

Journal of Parkinson’s Disease, 2014
Although nocturnal disturbances are increasingly recognized as an integral part of the continuum of daytime manifestations of Parkinson's disease (PD), there is still little evidence in the medical literature to support the occurrence of these complex ...
Roongroj Bhidayasiri, Onanong Jitkritsadakul, Carlo Colosimo   +2 more
doaj   +3 more sources

Toward Biology-Driven Diagnosis of Atypical Parkinsonian Disorders [PDF]

NeuroSci
Atypical parkinsonian disorders—progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA)—are rare, rapidly progressive neurodegenerative syndromes characterized by distinct molecular pathologies ...
Oscar Arias-Carrión, Elizabeth Romero-Gutiérrez, Emmanuel Ortega-Robles   +2 more
doaj   +2 more sources

Atypical parkinsonian disorders

Chinese Journal of Contemporary Neurology and Neurosurgery, 2011
DOI：10.3969/j.issn.1672-6731.2011.01 ...
Yue HUANG, Shengdi CHEN, Wenning Gregor, et al   +3 more
doaj   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA).
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills   +26 more
openaire   +3 more sources

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. [PDF]

Nat Aging, 2023
Pereira JB, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D, Parchi P, Mattsson-Carlgren N, Janelidze S, Hansson O.   +9 more
europepmc   +2 more sources

Advanced diffusion imaging to track progression in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy

NeuroImage: Clinical, 2022
Advanced diffusion imaging which accounts for complex tissue properties, such as crossing fibers and extracellular fluid, may detect longitudinal changes in widespread pathology in atypical Parkinsonian syndromes.
Trina Mitchell, Bradley J. Wilkes, Derek B. Archer, Winston T. Chu, Stephen A. Coombes, Song Lai, Nikolaus R. McFarland, Michael S. Okun, Mieniecia L. Black, Ellen Herschel, Tanya Simuni, Cynthia Comella, Mitra Afshari, Tao Xie, Hong Li, Todd B. Parrish, Ajay S. Kurani, Daniel M. Corcos, David E. Vaillancourt   +18 more
doaj   +1 more source